



July 11, 2025

DGM – Corporate Relations
BSE Limited.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001
Scrip Code: 500408

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C-1, Block G
Bandra – Kurla Complex, Bandra (East)
Mumbai – 400 051
Scrip Code: TATAELXSI

Dear Sirs/Madam,

Sub: Newspaper Publication of audited financial results of the Company for the quarter ended June 30, 2025

We herewith enclose copies of newspaper advertisement regarding extract of the audited financial results of the Company for the quarter ended June 30, 2025, published in 'Financial Express' and 'Udayakala' on July 11, 2025.

This Disclosure is made in terms of requirements of Regulation 30 and 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is also available on the website of the Company at www.tataelxsi.com

Yours faithfully,
For Tata Elxsi Limited

Sneha V
Company Secretary & Compliance Officer


Encl.: as above

TATA ELXSI

Registered Office **Tata Elxsi Limited** ITPB Road Whitefield Bangalore 560 048 India
Tel +91 80 2297 9123 Fax +91 80 2841 1474
www.tataelxsi.com



HINDUSTAN PETROLEUM CORPORATION LIMITED
(A Maharatna Company)
Regd. Office: Petroleum House, 17, Jamshedji Tata Road, Churchgate, Mumbai – 400 020
CIN: L23201MH1952GOI08858 Tel.: 022-22863201/3204
Email id: hpclinvestors@mail.hpcl.co.in Website: www.hindustanpetroleum.com



NOTICE TO SHAREHOLDERS
SPECIAL WINDOW FOR RE-LODGE MENT OF TRANSFER REQUESTS OF PHYSICAL SHARES

Pursuant to SEBI Circular dated July 02,2025, Shareholders who had lodged their transfer deeds of physical shares prior to the deadline of April 01, 2019 which were rejected/returned/not attended due to deficiency in the documents/process or otherwise and also missed to re-lodge their request before the cut-off date i.e. March 31, 2021 are granted one more opportunity for re-lodgement of transfer requests for a period of six months from July 07, 2025 to January 06, 2026.

During this special window period, the shares that are re-lodged for transfer shall be issued only in demat mode. Due process shall be followed for such transfer-cum-demat requests.

Shareholders are requested to re-submit their requests with our Registrar and Share Transfer Agent M/s MUFG Intime India Pvt. Ltd. (formerly Link Intime India Pvt. Ltd.) whose details are given below:


Postal Address: Unit: HPCL, C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083;


Contact No.: +91 8108116767

Email: mt.helpdesk@in.mfms.mufg.com


For Hindustan Petroleum Corporation Limited

Place: Mumbai V. Murali
Date : 11.07.2025 Company Secretary


www.hindustanpetroleum.com



GUJARAT GAS LIMITED
Registered Office: Gujarat Gas CNG Station, Sector 5/C, Gandhinagar – 382006, Gujarat. Tel: +91-79-26737400
website: www.gujaratgas.com
E-mail id: Investors@GUJARATGAS.com
CIN: L40200GJ2012SGC069118



NOTICE TO PHYSICAL SHAREHOLDERS - SPECIAL WINDOW FOR ONLY RE-LODGE MENT OF TRANSFER DEEDS OF PHYSICAL SHARES

Pursuant to SEBI circular No.SEBI/HO/MRSD/MRSD-PoD/PIR/2025/97 dated 2nd July, 2025, SEBI has decided to open a special window for a period of six months from 7th July, 2025 to 6th January, 2026 for only re-lodgment of transfer deeds by physical shareholders that were lodged prior to the deadline of 1st April, 2019 and rejected / returned due to deficiencies in the documents. Any transfer deeds which were lodged after deadline of 1st April, 2019 and rejected by the Company shall not be entertained by the Company.

Accordingly, in compliance to the said SEBI Circular, Notice is hereby given to the eligible physical shareholders of Gujarat Gas Limited to re-lodge share transfer deeds for transfer of shares on or before 6th January, 2026 and the share re-lodged for transfer will be processed only in dematerialized form after following due process prescribed by SEBI.

Eligible shareholder may submit their transfer requests along with the requisite documents to the Company's Registrar and Share Transfer agent (R&TA) at KFIN Technologies Limited, Unit Gujarat Gas Limited, Selenium Building, Tower-B, Plot No. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana, India - 500032 or E-mail at einward.ris@kfintech.com.

For, Gujarat Gas Limited
sd/-
Sandeep Dave
Company Secretary

Place: Gandhinagar
Date: 10th July, 2025



Scan above QR to view DRHP

ASSTON PHARMACEUTICALS LIMITED
Corporate Identification Number: U24304MH2019PLC324187

Our Company was originally incorporated as "Asston Pharmaceuticals Private Limited", a private limited company under Companies Act, 2013, pursuant to a certificate of incorporation dated April 16, 2019 issued by Registrar of Companies, Mumbai, Maharashtra. Thereafter, our Company was converted into a public limited company and the name of our Company was changed from "Asston Pharmaceuticals Private Limited" to "Asston Pharmaceuticals Limited" vide fresh certificate of incorporation dated August 29, 2024 issued by the Registrar of Companies, Mumbai, Maharashtra. The Corporate Identification Number of our Company is U24304MH2019PLC324187. For further details, please refer to chapter titled "History and Certain Corporate Matters" beginning on page 183 and 186 of this Draft Red Herring Prospectus and Red Herring Prospectus.

Registered Office: 4th Floor, Office No A-431, Balaji Bhavan, Plot No 42A Sector-11, CBD Belapur, Navi Mumbai, Thane – 400 614, Maharashtra, India.
Contact Person: Vandana Mishra, Company Secretary & Compliance Officer;
Tel: +91 22 49731411/+91 2249731419 | E-mail: info@asstonpharmaceuticals.com | Website: www.asstonpharmaceuticals.com/
CIN: U24304MH2019PLC324187

THE PROMOTERS OF OUR COMPANY ARE DR. ASHISH NARAYAN SAKALKAR, SAILI JAYARAM MORE AND SACHIN CHANDRAKANT BADA KH



Scan above QR to view RHP

THE ISSUE

INITIAL PUBLIC ISSUE OF 55,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH (THE "EQUITY SHARES") OF ASSTON PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "APL" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹[●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[●] LAKH ("PUBLIC ISSUE") OUT OF WHICH 1,13,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹[●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹[●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 52,16,000 EQUITY SHARES OF FACE VALUE OF ₹10 EACH, AT AN ISSUE PRICE OF ₹[●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹[●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.33% AND 25.00%, RESPECTIVELY OF THE POST- ISSUE PAID - UP EQUITY SHARE CAPITAL OF OUR COMPANY.

The Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, the Draft Red Herring Prospectus (DRHP) dated January 16, 2025 and Red Herring Prospectus (RHP) dated July 03, 2025 has been filed with BSE. In terms of the SEBI Regulations, the SEBI shall not issue any observation on the Offer Document. Hence there is no such specific disclaimer clause of SEBI. However, investors may refer to the entire "Disclaimer Clause of SEBI" beginning on page 235 of the DRHP and on page 241 of the RHP.




ATTENTION INVESTORS - CORRIGENDUM TO THE OFFER DOCUMENT

The Company filed the Draft Red Herring Prospectus (DRHP) on January 16, 2025, and subsequently filed the Red Herring Prospectus (RHP) with BSE Limited and the Registrar of Companies, Mumbai on July 03, 2025, in connection with its Initial Public Offering (IPO), which is scheduled to open for subscription on Wednesday, July 09, 2025, and close on Friday, July 11, 2025.

Attention of investors kindly refer the below mentioned point in furtherance to RHP:

- The litigation involving Mr. Ashish Narayan Sakalkar, one of the Promoters of the Company, is not a new proceeding but has already been disclosed under the "Outstanding Litigations and Material Developments" section of the RHP (refer page 221) under head Outstanding Litigations involving Group Companies of our Company on point V. The details have been further elaborated herein solely for the purpose of providing enhanced clarity and understanding to the public at large.
- Mr. Ashish Narayan Sakalkar, a promoter of the Company, is a defendant in a pending DRT case filed by Central Bank of India concerning a ₹48 lakh credit facility availed by Arient Scientific Pvt. Ltd., where he is also being prosecuted personally. Despite the bank taking possession of assets worth ₹90 lakhs, no effective action was taken, leading to asset deterioration. Arient underwent CIRP and was dissolved by NCLT Mumbai on 31st July 2024 due to lack of asset value and bids. All liquidation formalities are completed, and the matter is disclosed in the "Outstanding Litigations" section of the DRHP.
- The matter is currently pending at the Ex-Parte stage before DRT-3, Mumbai and Mr. Sakalkar is being prosecuted in personal capacity as well with the next date of hearing is 9th December, 2025.
- Our Employee count as on 30th September, 2024 is as below shall be refer as our Employee count as on 30th November, 2024 in DRHP on page number 172.
- The Company has paid ESIC and EPF dues since January 2025 after RHP filing, and all such details shall be updated in Prospectus and accordingly Risk Factor No. 9 of RHP will be changed.

GENERAL RISK: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this issue. For taking an investment decision, investors must rely on their own examination of the Issuer and this issue, including the risks involved. The Equity Shares have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 28 and 29 of the Draft Red Herring Prospectus and Red Herring Prospectus.

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <div>SOBHAGYA CAPITAL OPTIONS PVT. LTD. A SEBI Registered Merchant Banking Company</div> <div>SOBHAGYA CAPITAL OPTIONS PRIVATE LIMITED C-7 & C-7A, Gate No-01, Hosiyar Complex, Phase-II Extension, Noida-201305 Tel. No.: +91 7836068001 Email: cs@sobhagyacap.com Investor Grievance Email: delhi@sobhagyacap.com Website: www.sobhagyacapital.com Contact Person: Mr. Rishabh Singhvi/ Ms. Nisha SEBI Registration No.: MB/INM000008571</div>	 <div>MAASHITLA SECURITIES PRIVATE LIMITED 451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, Delhi- 110 034 Tel. Number: +91 11 47581432 Email: ipo@maashitla.com Website: www.maashitla.com Contact Person: Mr. Mukul Agrawal SEBI Reg. No.: INR000004370 CIN No: U67100DL2010PTC208725</div>	 <div>MS. VANDANA MISHRA: Company Secretary and Compliance Officer 4th Floor, Office No A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane – 400 614, Maharashtra, India. Telephone No.: +91 22 49731411/+91 2249731419; Website: www.asstonpharmaceuticals.com E-Mail: cs@asstonpharmaceuticals.com</div>

For ASSTON PHARMACEUTICALS LIMITED
sd/-
Dr. Ashish Narayan Sakalkar
Managing Director
DIN: 06601011

Place: Mumbai, Maharashtra
Date: July 10, 2025

Asston Pharmaceuticals Limited is proposing, subject to market conditions and other considerations, The Company has filed Draft Red Herring Prospectus on January 16, 2025 filed with BSE Limited and Red Herring Prospectus filed with the BSE Limited and Registrar of Companies, Mumbai on July 03, 2025. The Red Herring Prospectus is available on the website of the Book Running Lead Manager at www.sobhagyacapital.com, the website of the BSE i.e., www.bseindia.com, and website of our Company at <https://asstonpharmaceuticals.com>.

Investor should note that investment in equity shares involves a high degree of risk. For details, investors should refer to and rely on the Draft Red Herring Prospectus and Red Herring Prospectus, including the section titled "Risk Factors" of the Draft Red Herring Prospectus and Red Herring Prospectus, which has been filed with ROC. The Equity Shares have not been and will not be registered under the U.S. Securities Act ("the Securities Act") or any state securities laws in United States and may not be issued or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulations under the securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933.

AdBaz



TATA ELXSI LIMITED
CIN: L85110KA1989PLC009968
Regd. Office: ITPB Road, Whitefield, Bengaluru - 560 048
email: investors@tataelxsi.com; website: www.tataelxsi.com

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

The Board of Directors of Tata Elxsi Limited (the 'Company'), at its Meeting held on July 10, 2025, approved the audited financial results of the Company, for the quarter ended June 30, 2025.


The results, along with the Auditor's Report, have been posted on the Company's website at <https://www.tataelxsi.com/investors> and can be accessed by scanning the QR code.



By Order of the Board
for TATA ELXSI LIMITED
sd/-
Manoj Raghavan
Managing Director & CEO

Place : Bengaluru
Date : July 10, 2025

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.



(Please scan this QR Code to view the Draft Prospectus)

Vijaypdceutical LTD.
Connecting Healthcare, Delivering Hope

VIJAYPD CEUTICAL LIMITED
Corporate Identity Number: U21001MH2024PLC421713

Our Company was originally formed as a partnership firm under the name and style of "M/s. Vijay Pharma" pursuant to a deed of partnership dated October 05, 1971, as amended from time to time. Further, M/s. Vijay Pharma was converted into a public limited company "VijayPD Ceutical Limited" pursuant to the provisions of Chapter XXI of the Companies Act, 2013 and a fresh Certificate of Incorporation dated March 19, 2024, was issued by Assistant Registrar of Companies, Central Registration Centre. Further our Company has acquired the running business of M/s. P.D. Doshi, a Partnership firm on going concern basis vide Business Transfer Agreement dated April 01, 2024 entered by and between Samit Madhukar Shah, Rahul Jitendra Shah, Jigar Narendra Shah, Bhavin Dharendra Shah, Dharendra Chimanlal Shah and Nila Narendra Shah, on behalf of M/s. P.D. Doshi, Partnership firm and our company. The Corporate Identification Number of our Company is U21001MH2024PLC421713.

Registered Off.: A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai – 400062, Maharashtra, India.
Telephone: +91 9820917040 | Contact Person: Purvi Kishor Surti, Company Secretary and Compliance Officer
Email: investors@vijaypdceutical.com | Website: www.vijaypdceutical.com | Corporate Identity Number: U21001MH2024PLC421713

OUR PROMOTERS : SAMIT MADHUKAR SHAH, BHAVIN DHIRENDRA SHAH, RAHUL JITENDRA SHAH, NARENDRA NAGINDAS SHAH, DINA MADHUKAR SHAH, VASANTI DHIRENDRA SHAH AND HEMANTI JITENDRA SHAH

INITIAL PUBLIC OFFER OF 55,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF VIJAYPD CEUTICAL LIMITED ("OUR COMPANY" OR "VIJAYPD" OR "THE ISSUER") FOR CASH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE (THE "ISSUE PRICE") AGGREGATING TO ₹ 1,925.00 LAKHS ("THE ISSUE"), OF WHICH 2,84,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE AGGREGATING TO ₹ 99.40 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.e., NET ISSUE OF 52,16,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 35/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 25/- PER EQUITY SHARE AGGREGATING TO ₹ 1,825.60 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 28.16% AND 26.71% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

This Issue is being made through the Fixed Price Process, in terms of Rule 19(2)(b)(i) of the SCRR this Issue is being made for at least 25% of the post-Issue paid-up Equity Share capital of our Company. This Issue is being made through Fixed Price process in accordance and compliance with Chapter IX and other applicable provisions of SEBI ICDR Regulations wherein a minimum 50% of the Net Issue is allocated for individual investors who applies for minimum application size and the balance shall be offered to other than individual investors who applies more than minimum application size and other investors including corporate bodies or institutions, QIBs and Non-Institutional Investors. However, if the aggregate demand from the individual investors is less than 50%, then the balance Equity Shares in that portion will be added to the Other than Individual Investor portion offered to the remaining investors including QIBs and NIs and vice-versa subject to valid applications being received from them at or above the Issue Price. Additionally, if the individual investors category is entitled to more than 50% on proportionate basis, such investors shall be allocated that higher percentage. All potential investors shall participate in the issue only through an Application Supported by Blocked Amount ("ASBA") process including through UPI mode (as applicable) by providing details of the respective bank accounts and /or UPI IDs, in case of UPI Applicants, if applicable, which will be blocked by the Self Certified Syndicate Banks ("SCSBs") for the same. For details in this regard, specific attention is invited to "Issue Procedure" beginning on page 295 of the Draft Prospectus.

This Public announcement is being made in compliance with the regulation 247 of SEBI ICDR Regulation, 2018 read along with SEBI ICDR (Amendment) Regulation, 2025 and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME Companies for fulfilling all additional criteria, the DP filed with the SME Platform of National Stock Exchange of India Limited ("NSE Emerge") shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the NSE at www.nseindia.com, and the website of the Company at www.vijaypdceutical.com; and at the website of LM i.e. Smart Horizon Capital Advisors Private Limited at www.shcapl.com. Our Company hereby invites the members of the public to give their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and /or the LM at their respective addresses mentioned below. All comments must be received by NSE Emerge and/or our Company and /or LM in relation to the issue on or before 5 p.m. on the 21st day from the aforesaid date of filing the Draft Prospectus with NSE Emerge.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the issue. For taking an investment decision, investors must rely on their own examination of our Company and the issue, including the risks involved. The Equity Shares in the issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the contents of this Draft Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 31 of this Draft Prospectus.

Any decision to invest in the Equity Shares described in the Draft Prospectus may only be made after the Prospectus has been filed with the RoC and must be made solely on the basis of such Prospectus as there may be material changes in the Prospectus from the Draft Prospectus.

The Equity Shares, when offered, through the Prospectus, are proposed to be listed on EMERGE Platform of National Stock Exchange of India Limited (NSE Emerge).

For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 173 of the Draft Prospectus. The liability of the members of the Company is limited. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them see "Capital Structure" on page 72 of the Draft Prospectus.

LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <div>SMART HORIZON CAPITAL ADVISORS PRIVATE LIMITED (Formerly known as Shree Capital Advisors Private Limited) B/908, Western Edge II, Kanakia Space, Behind Metro Mall, off Western Express Highway, Magathane, Borivali East, Mumbai – 400066, Maharashtra, India. Tel No: 022-28706822 Email: director@shcapl.com Investors Grievance e-mail: investor@shcapl.com Contact Person: Parth Shah Website: www.shcapl.com SEBI Registration Number: INM000013183</div>	 <div>KFIN TECHNOLOGIES LIMITED Selenium Tower B, Plot 31-32, Financial District, Nanakramguda, Serilingampally Mandal, Hyderabad - 500 032, Telangana, India. Tel No: + 91-40-67162222 Email: vc.lpo@kfintech.com Website: www.kfintech.com Investor Grievance Email Id: einward.ris@kfintech.com Contact Person: M. Murali Krishna SEBI Registration Number: INR000000221</div>	 <div>VIJAYPD CEUTICAL LIMITED A/1, 1st Floor, Devraj Premises, CHSL, Goregaon West, Mumbai – 400062, Maharashtra, India. Tel. No.: +91 9820917040 Contact Person: Purvi Kishor Surti Email: investors@vijaypdceutical.com Website: www.vijaypdceutical.com Investors can contact our Company Secretary and Compliance Officer, Lead Manager or Registrar to the issue, in case of any pre issue or post issue related problems, such as non- receipt of letter of allotment, non- credit of allotted Equity shares in the respective beneficiary account, non-receipt of refund orders and non-credit of funds by electronic mode etc.</div>

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Prospectus.

For VijayPD Ceutical Limited
On behalf of the Board of Directors
sd/-
Samit Madhukar Shah
Chairman and Managing Director

Place: Mumbai
Date: July 10, 2025

VijayPD Ceutical Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the DP dated July 09, 2025 with NSE EMERGE. The DP is available on the website of NSE at www.nseindia.com and on the website of the LM, i.e., Smart Horizon Capital Advisors Private Limited at www.shcapl.com and the website of our Company at www.vijaypdceutical.com. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "Risk Factors" beginning on page 31 of the Draft Prospectus. Potential investors should not rely on the Draft Prospectus filed with NSE EMERGE for making any investment decision.

The Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933 (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

AdBaz



THE BIGGEST CAPITAL ONE CAN POSSESS



KNOWLEDGE



FINANCIAL EXPRESS

epaper.financialexpress.com

BENGALURU

